Innovations in treatment options for acute lymphoblastic leukemia (ALL) has improved patient outcomes with the optimization of multi-agent chemotherapy regimens through the use of asparaginase compounds, and more recently, the validation of newer agent classes, such as tyrosine kinase inhibitors, antibody-drug conjugates, bispecific antibodies, and adoptive cell therapy agents, has also led to better outcomes and enhanced care.

Looked at more closely, the development of antibody therapy in ALL and its integration into care can be considered a model for how to enhance standard treatment protocols over a range of settings, including induction/consolidation strategies prior to transplant, and as a way to induce deep, minimal residual disease-negative responses. In this PeerView “Tumor Board” symposium preceding the virtual 62nd ASH Annual Meeting and Exposition, leading hematology-oncology experts will discuss the most recent clinical evidence supporting modern antibody options in ALL, explore their increasing therapeutic applications, and gauge the progress in improving patient outcomes across a range of ALL populations and treatment settings. Register today for this important event!